Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

COVID-19 3Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Surveys and Questionnaires 114Exercise 103Blood Specimen Collection 99Radiotherapy 67Gemcitabine 64Bevacizumab 57Standard of Care 56Cisplatin 55Cyclophosphamide 51Capecitabine 50Carboplatin 49Docetaxel 47pembrolizumab 46Dexamethasone 46Paclitaxel 45Interviews as Topic 43Oxaliplatin 40Magnetic Resonance Spectroscopy 39Fluorouracil 37Methods 36Irinotecan 36Therapeutics 33Drug Therapy 33Radiosurgery 31Nivolumab 30Erlotinib Hydrochloride 27Educational Status 26Everolimus 24Leucovorin 23Control Groups 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasms × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05075538 2024-01-17

I-SPARC

Jules Bordet Institute

Phase 4 Terminated
152 enrolled

COVID-19, Neoplasms

NCT04930055 2023-05-19

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

Indiana University

Terminated
2,206 enrolled

COVID-19, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡